Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy

Treatment of cancer often requires the use of adjuvant chemotherapy (ACT). In real clinical practice, numerous patients suffer from severe toxicity and reduced quality of life (QoL). Hence, there is a need to maintain QoL and to reduce therapy toxicity to comply with recommended chemotherapy (CT) regimens. The present study focused on the effects of the multi-component nutritional supplement Oncoxin (ONCX) on QoL and CT-induced toxicity in patients undergoing ACT. A total of 133 patients aged 50-70 years with gastric cancer IIB-IIIC or non-small cell lung cancer IIB-IIIA were enrolled in the present study: 84 received ONCX, and 49 were included in the control arm and received CT only. It was identified that after 2 weeks of treatment the patients receiving ONCX exhibited clinically meaningful improvement of QoL (measured by Edmonton Symptom Assessment System Questionnaire) compared with those in the control group (odds ratio, 2.07; 95% CI, 1.00-4.29). By the end of a 3 week-period, the albumin level was higher in patients of the ONCX group compared with those in the control group (mean, 38.1; 95% CI, 37.1-39.1 g/l; vs. mean, 35.5; 95% CI, 33.9-37.0; P=0.03; respectively). Furthermore, the use of ONCX substantively reduced the hepatic toxicity of ACT. The present prospective real clinical setting study revealed positive effects of ONCX on QoL and ACT toxicity. The present study was retrospectively registered under the study registration number NCT03550482 at ClinicalTrials. gov (June 8, 2018). © 2019 Spandidos Publications. All rights reserved.

Authors
Kaidarova D.R.1 , Kopp M.V.2 , Pokrovsky V.S. 3 , Dzhugashvili M.4 , Akimzhanova Z.M.5 , Abdrakhmanov R.Z.1 , Babich E.N.6 , Bilan E.V.6 , Byakhov A.V.7 , Gurov S.N.8 , Koroleva I.A.2 , Mochalova A.S.9 , Povaga S.S.10 , Raigorodsky M.V.11 , Saifullin A.S.12 , Sanz E.13 , Petrovskiy F.I.14
Publisher
Spandidos Publications
Number of issue
5
Language
English
Pages
5644-5652
Status
Published
Volume
18
Year
2019
Organizations
  • 1 Kazakh Research Institute of Oncology and Radiology, Almaty, 050000, Kazakhstan
  • 2 Department of Clinical Medicine, Medical University 'Reaviz', Samara, 443001, Russian Federation
  • 3 Department of Biochemistry, N.N. Blokhin Cancer Research Center, RUDN University, Moscow, 115478, Russian Federation
  • 4 Department of Oncology Radiology, Murcia University, Murcia, 30200, Spain
  • 5 Department of Chemotherapy, Almaty Oncology Center, Almaty, 050060, Kazakhstan
  • 6 Department of Oncology, Khanty-Mansiysk Regional Clinical Hospital, Khanty-Mansiysk, 628012, Russian Federation
  • 7 Department of Chemotherapy, Moscow Clinical Scientific Center n. a. A.S. Loginov, Moscow, 111123, Russian Federation
  • 8 Department of Chemotherapy, Moscow Oncologic Clinical Dispensary No. 1, Moscow, 105005, Russian Federation
  • 9 Department of Chemotherapy, Clinical Hospital No. 1 MEDSI, Moscow, 143442, Russian Federation
  • 10 Department of Chemotherapy, Russian Railways Hospital, Station Smolensk, Smolensk, 214025, Russian Federation
  • 11 Department of Oncology, Medical Center 'EVIMED' LLC, Chelyabinsk, 454048, Russian Federation
  • 12 Department of Chemotherapy, Surgut Regional Hospital, Surgut, 628400, Russian Federation
  • 13 Scientific Department, Catalysis S.L., Madrid, 28016, Spain
  • 14 Department of Pharmacology and Clinical Pharmacology, Khanty-Mansiysk State Medical Academy, Mira Street 40, Khanty-Mansiysk, 628011, Russian Federation
Keywords
Adjuvant chemotherapy; Oncoxin; Quality of life; Therapy toxicity
Share

Other records